Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 GBS6 vaccine in pregnant women and infants
jRCT2051250116Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in Streptococcus agalactiae infection (GBS) comparing GBS6 vaccine with Placebo (2 arms). Primary endpoints: Maternal local reactions within 7 days, Maternal systemic events within 7 days and 12 more. Started Oct 2025; status: recruiting.
02
Drugs
GBS6
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on jRCT2051250116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250116.